Abstract
RAS association domain family protein 1a (RASSF1A) is a putative tumor suppressor gene located on 3p21, has been regarded playing important roles in the regulation of different types of human tumors. Previous reports demonstrated that the frequency of RASSF1A methylation was significantly higher in patients group compared with controls, but the relationship between RASSF1A promoter methylation and pathological features or the tumor grade of bladder cancer remains controversial. Therefore, A meta-analysis of published studies investigating the effects of RASSF1A methylation status in bladder cancer occurrence and association with both pTNM (p, pathologic stage; T, tumor size; N, node status; M, metastatic status) and tumor grade in bladder cancer was performed in the study. A total of 10 eligible studies involving 543 cases and 217 controls were included in the pooled analyses. Under the fixed-effects model, the OR of RASSF1A methylation in bladder cancer patients, compared to non-cancer controls, was 8. 40 with 95%CI = 4. 96–14. 23. The pooled OR with the random-effects model of pTNM and tumor grade in RASSF1A methylated patients, compared to unmethylated patients, was 0. 75 (95%CI = 0. 28–1. 99) and 0. 39 (95%CI = 0. 14–1. 09). This study showed that RASSF1A methylation appears to be an independent prognostic factor for bladder cancer. The present findings also require confirmation through adequately designed prospective studies.
Highlights
Bladder cancer is the most common malignancy of the urinary tract, and the 9th most common cancer diagnosis worldwide, with more than 330, 000 new cases each year and more than 130, 000 deaths per year
This study showed that RAS association domain family protein 1a (RASSF1A) methylation appears to be an independent prognostic factor for bladder cancer
Study Characteristics According to our inclusion criteria, a total of 10 eligible studies[22,23,24,25,26,27,28,29,30,31] involving 543 cases and 217 controls were included in the pooled analyses
Summary
Bladder cancer is the most common malignancy of the urinary tract, and the 9th most common cancer diagnosis worldwide, with more than 330, 000 new cases each year and more than 130, 000 deaths per year. RASSF1A, one of the seven different isoforms of RASSF1, is a putative tumor suppressor gene located on 3p21, a region of common heterozygous and homozygous deletions in different types of human tumors [5,6]. It shares high sequence homology with a known mouse protein (Nore1) and may serve as an effector that mediates the apoptotic effects by binding Ras in a guanosine triphosphate-dependent manner [6]. RASSF1A methylation was reported as a prognostic indicator in renal cell carcinoma, non-small cell lung cancer, neuroblastoma, melanoma, endometrial cancer and
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
